According to the latest report by IMARC Group, titled “Non-Invasive Prenatal Testing (NIPT) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” offers a comprehensive analysis of the industry, which comprises insights on the market. The non-invasive prenatal testing market research report also includes competitor and regional analysis, and contemporary advancements in the market. The global non-invasive prenatal testing market size reached US$ 3.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.5 Billion by 2028, exhibiting a growth rate (CAGR) of 17.2% during 2023-2028.
Non-Invasive Prenatal Testing (NIPT) Market Overview:
Non-invasive prenatal testing (NIPT) refers to a screening method that is generally conducted on pregnant women to detect the risks of specific genetic abnormalities in the fetus. It is generally done for fetal chromosomal aneuploidies in order to analyze cell-free deoxyribonucleic acid (DNA) circulation in maternal blood. Besides this, it is widely preferred over other screening processes, especially for trisomy 21 and individuals who are at a higher risk of fetal chromosomal abnormalities. It involves several tests, including ultrasound detection, cell-free DNA and fetal cells in maternal blood and biochemical screening tests.
Additionally, it is also used to determine genetic and chromosomal disorders, such as triploidy aneuploidy, Patau, Jacob’s, down, Klinefelter, Turners, and Edwards syndromes. It is highly preferred to make an informed decision associated with diagnostic testing while minimizing the need for precarious and invasive procedures. Consequently, it provides low-false positive rates with higher accuracy, sensitivity, and specificity while reducing the risk of miscarriage.
Request Free Sample Report (Exclusive Offer on this report): https://www.imarcgroup.com/non-invasive-prenatal-testing-market/requestsample
Global Non-Invasive Prenatal Testing Market Trends:
The growing birth rate across the globe majorly drives the market. Coupled with the rising prevalence of fetal chromosomal abnormalities is one of the major factors driving the market. With the growing awareness among parents, the demand for early non-invasive prenatal testing (NIPT) is rapidly increasing, thereby impacting the market growth.
Apart from this, several initiatives undertaken by the governments of numerous countries, including the inclusion of NIPT in public health policies and budget allocation for average-risk pregnancies, are offering lucrative opportunities to the key players. Since obstetricians are recommending non-invasive tests as an alternative to various invasive methods, along with the rising preference for initial diagnostic screening in the first trimester of pregnancy, this, in turn propelling the growth of the market.
Furthermore, continual technological advancements on the global level have encouraged leading players to heavily invest in novel technologies. For instance, the widespread integration of artificial intelligence (AI) and deep neural networks with NIPT to assist healthcare professionals in decision-making in difficult-to-call cases and also aid in accurate detection of aneuploidies and microdeletions in the fetus. Some of the other factors driving the market growth include rising health consciousness among parents, significant improvements in the healthcare infrastructure, and continual advancements in the field of next-generation sequencing (NGS).
Key Market Segmentation:
Top Companies In Non-Invasive Prenatal Testing Market:
- Agilent Technologies Inc.
- Berry Genetics Inc.
- BGI Genomics Co. Ltd.
- Eurofins LifeCodexx GmbH
- F. Hoffmann-La Roche AG
- GE Healthcare, Igenomix
- Illumina Inc.
- Laboratory Corporation
- Natera Inc.
- Perkinelmer Inc.
- Thermo Fisher Scientific Inc.
- Yourgene Health
Breakup by Product Type:
- Consumables
- Instrument
Breakup by Test Type:
- Materni 21
- Harmony
- Panaroma
- Verifi
- NIFTY
- Others
Breakup by Technology:
- NGS
- WGS
- Others
Breakup by Test Type:
- Ultrasound Detection
- Biochemical Screening Tests
- Cell-Free DNA in Maternal Plasma Tests
- Fetal Cells in Maternal Blood Tests
- Others
Breakup by Application:
- Trisomy
- Microdeletions Syndrome
- Others
Breakup by End-User:
- Hospitals
- Diagnostic Laboratories
- Others
Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (Germany, France, United Kingdom, Italy, Spain, Others)
- Europe (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
For more content visit here:- https://cityoftips.com/
